

IRB approval for US COVID-19 study modification

- **ResApp has received IRB approval to modify its US COVID-19 study to allow for recruitment at in-person COVID-19 testing clinics**
- **ResApp has partnered with Covid Clinic, a nationwide network of COVID-19 testing sites that provides the most comprehensive and robust suite of COVID-19 tests for patients of all ages**

Brisbane, Australia, 15 November 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received Institutional Review Board (“IRB”) approval to modify its US-based SARS-CoV2 (“COVID-19”) clinical study, COVID-Cough, to allow for recruitment at in-person COVID-19 testing clinics.

ResApp has partnered with Covid Clinic to recruit 100 COVID-19 PCR-confirmed subjects at seven of its COVID-19 testing clinics in California. Covid Clinic is a nationwide network of COVID-19 testing sites with well over 100 locations in the US and has extensive experience in performing COVID-19 research studies.

The US-based COVID-Cough pilot clinical study (clinicaltrials.gov: NCT04864535) aims to secure data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a gold standard PCR pathology test as a reference standard.

The COVID-Cough study aims to recruit up to 1,500 subjects in the US with recruitment in the study expected to complete mid-December 2021.

CEO and Managing Director, Dr Tony Keating said: *“Adding the option of recruiting patients at in-person COVID-19 testing clinics will substantially increase our recruitment rate and gives us a high level of confidence that we will complete recruitment by mid-December. With our study in India also recruiting exceptionally well, we are pleased to have a growing dataset of patients from multiple continents to perform the algorithm training and validation processes needed to build an instant smartphone-based screening test for COVID-19.”*

###

About Covid Clinic

Covid Clinic is a nationwide network of COVID-19 testing sites that started as a grassroots effort to step into the community health breach as the global pandemic began to ravage the United States in March of 2020. This undertaking, spearheaded by a group of caring individuals and healthcare workers in Southern California, started with next to nothing to begin testing patients in the community. Covid Clinic has locations across the United States and provides the most

comprehensive and robust suite of COVID-19 tests for patients of all ages. Covid Clinic's dedicated, caring staff has administered over hundreds of thousands of tests, in the fight against COVID-19, and helped communities heal and stop the spread of the virus. Beyond COVID-19 testing, Covid Clinic plans to continue their community healthcare outreach efforts and expand their future testing offerings to include drugs, alcohol, pregnancy, and diseases such as tuberculosis, especially in underserved communities.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.